Assessing the performance of a specific hip implant in patients needing hip replacement
Official title: Étude Prospective, Multicentrique, Non contrôlée, Non randomisée, Ouverte évaluant la Performance et la stabilité de l'Implant fémoral Non cimenté SMS
Run by Medacta International SA · NCT06640764 · Data updated 2026-11-12
This study tests how well a new hip implant works for people with severe hip pain who need a hip replacement.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 260 (estimated) |
| Sponsor | Medacta International SA Industry-sponsored |
| Locations | 1 site (Saint-Jean) |
| Status | Recruiting |
| Started | September 1, 2024 |
| Main results expected | September 1, 2034 |
| Study ends | September 1, 2037 |
| Registry record updated | October 8, 2026 |
| Trial ID | NCT06640764 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 with severe hip joint pain requiring total hip replacement due to specific conditions.
✕Probably not a fit
Patients with acute infections, significant anatomical deformities, or those who are pregnant or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the performance and stability of the Medacta SMS femoral stem in patients suffering from severe hip joint pain due to conditions like osteoarthritis and avascular necrosis. It involves multiple centers and focuses on patients who require total hip arthroplasty. Participants will be monitored for their outcomes following the implantation of the femoral stem, providing valuable data on its effectiveness and safety.
Why it matters
Potential benefit: If successful, this study could lead to improved outcomes for patients undergoing hip replacement surgery.
How similar studies have gone: While this study is focused on a specific implant, similar observational studies have shown promising results in evaluating hip replacement technologies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient suffering from a severely painful and/or disabling hip joint due to osteoarthritis, traumatic arthritis, developmental dysplasia of the hip, or avascular necrosis of the femoral head, and requiring a total hip replacement. * Patient who will receive a Medacta SMS femoral stem. * Patient agrees to comply with the study requirements. * Patient has signed the consent form. * Patient is affiliated with a social security system. * Patient aged 18 to 75 years Exclusion Criteria: * Participation in biomedical research. * Minor patient. * Protected adult patient. * Vulnerable individuals as defined by Article L1121-6 of the Public Health Code. * Pregnant or breastfeeding women. * Patient unable to express their non-opposition. * Patient refusing the collection of their personal data. * Acute, systemic, or chronic infection. Skeletal immaturity. * Grossly deformed anatomy (at the surgeon's discretion). * Osteomalacia for which the fixation of an uncemented implant is contraindicated. * Patient suffering from active rheumatoid arthritis or osteoporosis. * Patient with metabolic disorders likely to impair bone formation when the fixation of an uncemented implant is contraindicated. * Patient suffering from muscle atrophy or neuromuscular disease. * Patient with an allergy to the implant material. * Any patient who cannot or does not wish to give their informed consent to participate in the study. * Patient whose prospects of regaining independent mobility would be compromised by known coexisting medical problems. * Any contraindication mentioned in the instructions for use of the investigational medical device.
Where it's running
-
Clinique de l'Union
Saint-Jean, France Recruiting
Study contacts
- Study coordinator: Paul Maisongrosse
- Email: paul.maisongrosse@hotmail.fr
- Phone: 0033 05 61 37 85 93
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Povidone-iodine versus chlorhexidine wound wash after total hip replacement
We will test whether washing the surgical wound with povidone-iodine or chlorhexidine helps wounds heal better after total hip replacement in people with hip osteoarthritis or avascular necrosis of the femoral head.
-
Ceramic hip resurfacing vs total hip arthroplasty for hip OA
This trial tests whether ceramic hip resurfacing helps people with hip OA walk farther each day than a modern total hip replacement.
-
Dexmedetomidine during hip replacement to modulate nerves and inflammation
A randomized, placebo-controlled study tests whether intravenous dexmedetomidine given during spinal anesthesia with a PENG nerve block can help regulate the body's stress and inflammatory response and improve recovery after hip replacement.
-
Preoperative Fasting to Shape the Gut with Hip Replacement
This trial tests whether a 20-day preoperative fasting plan can lower inflammatory signals and broaden gut microbes in adults undergoing total hip arthroplasty.
-
Cryoneurolysis for Chronic Pain: 6- and 12-Month Outcomes in Routine Care
This study tests whether cryoneurolysis, done as part of standard care for people with chronic pain, leads to meaningful improvements over 6 to 12 months.
-
Spinal anesthesia with intrathecal morphine vs PENG block (with or without dexamethasone) for hip replacement
In people aged 60 and older undergoing total hip arthroplasty, this study tests whether three anesthesia approaches provide better pain control and fewer side effects: spinal with intrathecal morphine, spinal with a PENG block, or spinal with a PENG block plus dexamethasone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.